TY - JOUR
T1 - A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study
AU - Wentzensen, Nicolas
AU - Rodriguez, Ana Cecilia
AU - Viscidi, Raphael
AU - Herrero, Rolando
AU - Hildesheim, Allan
AU - Ghosh, Arpita
AU - Morales, Jorge
AU - Wacholder, Sholom
AU - Guillen, Diego
AU - Alfaro, Mario
AU - Safaeian, Mahboobeh
AU - Burk, Robert D.
AU - Schiffman, Mark
N1 - Funding Information:
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, and 2Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland; 3Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, and 4Proyecto Epidemiológico Guanacaste, Costa Rica
PY - 2011/7/1
Y1 - 2011/7/1
N2 - Background. A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. Methods. In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. Results. cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). Conclusions. Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.
AB - Background. A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. Methods. In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. Results. cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). Conclusions. Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.
UR - http://www.scopus.com/inward/record.url?scp=79957953906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957953906&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir209
DO - 10.1093/infdis/jir209
M3 - Article
C2 - 21628663
AN - SCOPUS:79957953906
SN - 0022-1899
VL - 204
SP - 94
EP - 102
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -